T. Seiwert

发表

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

J. Lunceford, Chunsheng Zhang, T. Mcclanahan, 2018, Science.

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.

E. Vokes, T. Seiwert, D. Haraf, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Accurate HPV testing: a requirement for precision medicine for head and neck cancer.

T. Seiwert, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive genomic characterization of head and neck squamous cell carcinomas

Steven J. M. Jones, Joshua M. Stuart, Thomas M. Harris, 2015, Nature.

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

R. Berger, M. Dolled-Filhart, T. Seiwert, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

Petar Stojanov, Kevin P. White, Christopher D. Brown, 2014, Clinical Cancer Research.

Immune profiles in primary squamous cell carcinoma of the head and neck.

Yusuke Nakamura, A. Zhavoronkov, Michael Korzinkin, 2019, Oral oncology.

Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?

A. Cmelak, R. Ferris, T. Seiwert, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

T. Seiwert, D. Pfister, J. Gilbert, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Jonathan C. Cheng, T. Seiwert, R. Mehra, 2018, British Journal of Cancer.

Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

Yusuke Nakamura, N. Cipriani, E. Vokes, 2017, Clinical Cancer Research.

Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing.

T. Seiwert, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

T. Seiwert, E. Cohen, D. Cupissol, 2010 .

Variations in HPV function are associated with survival in squamous cell carcinoma.

Jing Wang, Y. Xi, J. Califano, 2019, JCI insight.

Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma.

Daria A. Gaykalova, A. Pearson, A. Chatterjee, 2019, Cancer letters.

The Role of HGF/c-MET in Head and Neck Squamous Cell Carcinoma

R. Salgia, T. Seiwert, T. Beck, 2014 .

A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.

E. Vokes, N. Foster, G. Schwartz, 2021, Oral oncology.

Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions.

T. Seiwert, C. Fakhry, Elaine O Bigelow, 2020, Oral oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

MET/PKCß expression correlate with metastasis and inhibition is synergistic in lung cancer

M. Westerhoff, R. Salgia, E. Vokes, 2009, Journal of carcinogenesis.

A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer

R. Salgia, E. Vokes, T. Seiwert, 2007, Clinical Cancer Research.

Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).

T. Seiwert, T. Karrison, A. Desai, 2018 .

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors

J. Lunceford, T. Mcclanahan, M. Ayers, 2015, Journal of Immunotherapy for Cancer.

Optima: A phase II dose and volume de-escalation trial for high- and low-risk HPV+ oropharynx cancers.

E. Vokes, T. Seiwert, D. Haraf, 2017 .

EGFR-directed treatments in SCCHN.

E. Vokes, T. Seiwert, 2013, The Lancet. Oncology.

A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.

M. Dolled-Filhart, K. Emancipator, T. Seiwert, 2014 .

Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies.

T. Seiwert, S. Dietrich, P. Ma, 2005, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

E. Vokes, T. Seiwert, J. Bauman, 2020, Cancer.

Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.

M. Maitland, M. Ratain, G. Bakris, 2013, The oncologist.

Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients.

J. Lunceford, T. Mcclanahan, M. Ayers, 2015 .

Role of dental hardware in oral cavity squamous cell carcinoma in the low‐risk nonsmoker nondrinker population

N. Cipriani, E. Vokes, T. Seiwert, 2018, Head & neck.

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

V. Velculescu, Q. K. Li, V. Anagnostou, 2022, Journal for ImmunoTherapy of Cancer.

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

T. Seiwert, J. Vermorken, P. Szturz, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.

E. Vokes, T. Seiwert, D. Haraf, 2016, International journal of radiation oncology, biology, physics.

Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma

A. Pearson, E. Vokes, T. Seiwert, 2022, British Journal of Cancer.

A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and

E. Vokes, T. Seiwert, D. Haraf, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

C. R. Leemans, J. Machiels, P. Bruzzi, 2019, Journal of Immunotherapy for Cancer.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

E. Vokes, T. Seiwert, D. Haraf, 2019, Annals of Oncology.

Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation

E. Vokes, T. Seiwert, K. Choe, 2011, Cancer.

A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer

E. Vokes, T. Seiwert, R. Brisson, 2019, Head & neck.

Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.

T. Seiwert, M. Hwang, 2021, The Lancet. Oncology.

Development of a web-based, patient-centered decision aid for oropharyngeal cancer treatment.

T. Seiwert, C. Fakhry, Melina J. Windon, 2021, Oral oncology.

Biomarker-driven indication selection in JTX-2011 ICONIC clinical trial.

H. Hirsch, T. Seiwert, S. Sathyanarayanan, 2017 .

Phase 2 study of sunitinib in refractory thyroid cancer

E. Vokes, T. Seiwert, V. Villaflor, 2008 .

Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab

E. Vokes, T. Seiwert, V. Villaflor, 2015, Cancer Immunology Research.

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.

G. Pelosi, T. Seiwert, M. Lingen, 2015, Cancer letters.

T. Seiwert, R. Brisson, Y. Tan, 2021, Cancer.

Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin

T. Seiwert, M. Lingen, M. Rosner, 2011, Head & neck.

We appreciate the comments from Chakraborty and Patil 1 re- garding the DeCIDE (Docetaxel Based Chemotherapy Plus or Minus InductionChemotherapytoDecreaseEventsinHeadandNeckCan-

T. Seiwert, D. Haraf, T. Karrison, 2015 .

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies

E. Vokes, T. Seiwert, D. Haraf, 2011, Head & neck oncology.

DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN).

E. Vokes, T. Seiwert, R. Mehra, 2012 .

A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer

C. Obasaju, R. Salgia, E. Vokes, 2005 .

Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer

T. Seiwert, D. Pardoll, W. Koch, 2021, Cancers.

OA13.02 Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis

T. Seiwert, T. Karrison, H. Kindler, 2017 .

Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522)

E. Vokes, T. Seiwert, D. Haraf, 2019 .

Biomarkers predictive of response to pembrolizumab in head and neck cancer

J. Lunceford, M. Ayers, R. Cristescu, 2022, Cancer medicine.

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

J. Machiels, T. Seiwert, A. Psyrri, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).

T. Seiwert, D. Pfister, J. Gilbert, 2016 .

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

Liang Zhao, T. Seiwert, A. Pal, 2022, Science advances.

Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis

T. Seiwert, G. Zhu, Donghai Huang, 2021, Frontiers in Immunology.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

J. Lunceford, T. Mcclanahan, R. Berger, 2016, The Lancet. Oncology.

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

J. Lunceford, T. Mcclanahan, J. Juco, 2017, Clinical Cancer Research.

Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)

R. Cristescu, R. Mogg, A. Webber, 2018, Clinical Research (Excluding Clinical Trials).

J. Lunceford, T. Mcclanahan, M. Ayers, 2017, The Journal of clinical investigation.

The chemoradiation paradigm in head and neck cancer

Joseph K Salama, E. Vokes, T. Seiwert, 2007, Nature Clinical Practice Oncology.

A value framework in head and neck cancer care.

T. Seiwert, J. D. de Souza, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

State-of-the-art management of locally advanced head and neck cancer

T. Seiwert, E. Cohen, T Y Seiwert, 2005, British Journal of Cancer.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

M. Zauderer, R. Yeh, J. Ware, 2016, Clinical Cancer Research.

Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma.

Christopher D. Brown, K. White, E. Vokes, 2015, Oral oncology.

Molecular targeted therapies in head and neck cancer - An update of recent developements -

Holger Sudhoff, H. Sudhoff, T. Seiwert, 2010, Head & neck oncology.

Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer

J. Deeks, T. Seiwert, C. West, 2019, Clinical Cancer Research.

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

B. O'Sullivan, N. Lee, M. Chua, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

E. Vokes, T. Seiwert, R. Mehra, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.

R. Weichselbaum, E. Vokes, T. Seiwert, 2014, Oral oncology.

Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix

F. Klauschen, I. Tinhofer, T. Seiwert, 2016, Oncotarget.

J. Lunceford, T. Mcclanahan, M. Ayers, 2019 .

Expression and mutational analysis of MET in human solid cancers

J. Christensen, R. Salgia, E. Vokes, 2008, Genes, chromosomes & cancer.

Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors.

D. Hayes, C. Van Waes, T. Seiwert, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Persistent mutation burden drives sustained anti-tumor immune responses

V. Velculescu, R. Karchin, V. Anagnostou, 2023, Nature Medicine.

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

J. Lunceford, M. Ayers, R. Cristescu, 2022, Journal for ImmunoTherapy of Cancer.

Mechanism of acquired resistance to cetuximab in head and neck cancer.

E. Vokes, T. Seiwert, M. Lingen, 2018 .

Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes

Kevin P. White, Christopher D. Brown, Damian Rieke, 2014, Clinical Cancer Research.

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.

David L. Masica, R. Yelensky, R. Karchin, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Tumor Site With the Prognosis and Immunogenomic Landscape of Human Papillomavirus-Related Head and Neck and Cervical Cancers.

T. Seiwert, D. Pardoll, W. Koch, 2021, JAMA otolaryngology-- head & neck surgery.

916MO Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC)

T. Seiwert, J. Boyer, A. Algazi, 2020 .

Targeting angiogenesis in head and neck cancer.

T. Seiwert, E. Cohen, 2008, Seminars in oncology.

HPV-Associated Head and Neck Cancer.

E. Vokes, T. Seiwert, N. Agrawal, 2015, Journal of the National Cancer Institute.

Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic.

T. Stricker, T. Seiwert, D. Catenacci, 2011, Seminars in oncology.

Christopher R. Schmidt, C. Plass, N. Grabe, 2013, The Journal of clinical investigation.

mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas

S. Hewitt, T. Seiwert, J. S. Gutkind, 2012, Clinical Cancer Research.

Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.

A. Pearson, N. Cipriani, E. Vokes, 2021, Oral oncology.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

E. Vokes, T. Seiwert, D. Haraf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The concurrent chemoradiation paradigm—general principles

Joseph K Salama, E. Vokes, T. Seiwert, 2007, Nature Clinical Practice Oncology.

Targeted Therapies in Head and Neck Cancer

T. Seiwert, E. Cohen, 2005 .

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†

T. Seiwert, R. Hitt, E. Cohen, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation

R. Salgia, M. Tretiakova, T. Seiwert, 2006, Nature Clinical Practice Oncology.

MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma

R. Bueno, R. Salgia, Frances E. Lennon, 2014, PloS one.

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.

G. Gordon, D. Sugarbaker, R. Bueno, 2006, Cancer research.

Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

R. Ferris, T. Seiwert, J. Moy, 2017, The oncologist.

Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Jacob I Tower, T. Seiwert, M. Lingen, 2014, American journal of translational research.

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma

Y. Bang, R. Salgia, E. Vokes, 2011, Cancer biology & therapy.

Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays.

Michelle N Wurst, Larissa V Furtado, Megan E. McNerney, 2017, The Journal of molecular diagnostics : JMD.

Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.

Stuart Schwartz, Luc Girard, Ravi Salgia, 2008, Cancer research.

DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer

R. Weichselbaum, E. Vokes, T. Seiwert, 2014, PloS one.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

J. Christensen, R. Salgia, E. Vokes, 2009, Cancer research.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

A. Jimeno, J. Machiels, T. Seiwert, 2016, Cancer.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.

R. Berger, T. Seiwert, R. Mehra, 2016 .

Chemoradiotherapy for locally advanced head and neck cancer.

E. Vokes, T. Seiwert, J. Salama, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.

Megan E. McNerney, K. White, M. McNerney, 2013, Oral oncology.

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

T. Seiwert, H. Keer, G. Blumenschein, 2012, Investigational New Drugs.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

J. Dancey, E. Vokes, T. Seiwert, 2009, The Lancet. Oncology.

Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.

T. Seiwert, J. Hess, Zhixiang Zuo, 2016, Oral oncology.

Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.

E. Vokes, T. Seiwert, D. Haraf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Protein kinase C beta in malignant pleural mesothelioma

M. Westerhoff, R. Salgia, E. Vokes, 2008, Anti-cancer drugs.

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

T. Seiwert, N. Saba, M. Esser, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review

T. Seiwert, D. Pardoll, G. Zhu, 2021, Head & neck.

Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Post-Treatment Functional Outcomes.

E. Vokes, T. Seiwert, D. Haraf, 2020, International journal of radiation oncology, biology, physics.

Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).

M. Ayers, R. Cristescu, R. Mogg, 2017 .

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

R. Weichselbaum, E. Vokes, T. Seiwert, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathway in Malignant Pleural Mesothelioma Functional Analysis of c-Met / Hepatocyte Growth Factor

G. Gordon, D. Sugarbaker, R. Bueno, 2005 .

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.

R. Weichselbaum, Helen X. Chen, E. Vokes, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spontaneous regression of an human papillomavirus‐positive oropharyngeal squamous cell carcinoma

T. Seiwert, C. Fakhry, L. Rooper, 2022, Head & neck.

Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer

Yong Huang, Yves A. Lussier, Jianrong Li, 2012, PLoS Comput. Biol..

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Prognostic value of pre-treatment CT texture analysis in combination with change in size of the primary tumor in response to induction chemotherapy for HPV-positive oropharyngeal squamous cell carcinoma.

M. Giger, L. Lan, Hui Li, 2019, Quantitative imaging in medicine and surgery.

Biomarkers of pembrolizumab (P) activity in mesothelioma (MM): Results from a phase II trial.

T. Seiwert, T. Karrison, H. Kindler, 2017 .

Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

A. Pearson, S. Salas, T. Seiwert, 2020 .

Time to Debunk an Urban Myth? The "Abscopal Effect" With Radiation and Anti-PD-1.

T. Seiwert, A. Kiess, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.

H. Hirsch, F. Meric-Bernstam, G. Gibney, 2018 .

Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.

E. Vokes, T. Seiwert, D. Haraf, 2018, Oral oncology.

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Jeffrey Bozeman, J. Dancey, E. Vokes, 2012, Clinical Cancer Research.

Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma

Yusuke Nakamura, E. Vokes, Jae-Hyun Park, 2019, Oncoimmunology.

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma

R. Weichselbaum, R. Salgia, E. Vokes, 2016, Oncotarget.

Interrogation of T Cell–enriched Tumors Reveals Prognostic and Immunotherapeutic Implications of Polyamine Metabolism

E. Fertig, T. Seiwert, D. Pardoll, 2021, medRxiv.

Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer.

Yusuke Nakamura, P. Hegde, E. Vokes, 2014 .

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

J. Machiels, M. Ahn, T. Seiwert, 2016 .

WHSC 1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck

Yusuke Nakamura, T. Tsunoda, J. Licht, 2015 .

WHSC1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck

Yusuke Nakamura, T. Tsunoda, J. Licht, 2014, Molecular Cancer Research.

A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.

O. Harismendy, E. Vokes, T. Seiwert, 2022, Clinical Cancer Research.

A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.

E. Vokes, T. Seiwert, J. Bauman, 2015 .

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition

O. Olopade, T. Seiwert, T. Wei, 2013, Molecular oncology.

Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Lunceford, M. Ayers, R. Berger, 2016 .

Chemoradiation for patients with large‐volume laryngeal cancers

E. Vokes, T. Seiwert, D. Haraf, 2012, Head & neck.

Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.

A. Pearson, E. Vokes, T. Seiwert, 2021 .

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.

R. Yelensky, R. Karchin, C. Tokheim, 2015 .

OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis

T. Seiwert, T. Karrison, A. Desai, 2018, Journal of Thoracic Oncology.

Title: WHSC1 Promotes Oncogenesis through Regulation of NIMA-related-kinase-7 in Squamous Cell Carcinoma of the Head and Neck

Yusuke Nakamura, T. Tsunoda, J. Licht, 2014 .

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

G. Gibney, T. Seiwert, M. Callahan, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genomic biomarkers in relation to PD-1 checkpoint blockade response.

J. Lunceford, Chunsheng Zhang, T. Mcclanahan, 2018 .

The role of macrophages in the tumor microenvironment and tumor metabolism

T. Seiwert, P. Sadhukhan, 2023, Seminars in Immunopathology.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

T. Seiwert, R. Mehra, L. Chow, 2018, British Journal of Cancer.

A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study

E. Vokes, T. Seiwert, W. Stadler, 2020, Cancer.

Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy

A. Jimeno, S. Salas, T. Seiwert, 2018, Clinical Trials.

An Immunogenomic Investigation of Oral Cavity Squamous Cell Carcinoma in Patients Aged 45 Years and Younger

T. Seiwert, D. Pardoll, W. Koch, 2020, The Laryngoscope.

A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer

E. Vokes, T. Seiwert, D. Haraf, 2007, Cancer investigation.

Clinical Uncertainties of Circulating Tumor DNA in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma in the Absence of National Comprehensive Cancer Network Guidelines.

T. Seiwert, H. Quon, C. Kut, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract B6: A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5‐days‐on/9‐days‐off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck

P. Bonate, T. Seiwert, S. Swann, 2009 .

Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapy.

Christopher D. Brown, K. White, E. Vokes, 2012 .

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.

T. Seiwert, R. Hitt, E. Cohen, 2014 .

A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC).

H X Chen, R. Weichselbaum, E. Vokes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.

O. Olopade, E. Vokes, T. Seiwert, 2012, Oral Oncology.

A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.

T. Seiwert, J. Caudell, Colette J. Shen, 2021 .

Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.

J. Burke, A. Tolcher, G. Gibney, 2017 .

OPTIMA—A Phase 2 Trial of Induction Chemotherapy Response-Stratified Radiation Therapy Dose and Volume De-escalation for HPV+ Oropharyngeal Cancer: Efficacy, Toxicity, and HPV Subtype Analysis

E. Vokes, T. Seiwert, D. Haraf, 2018 .

J. Lunceford, T. Mcclanahan, M. Ayers, 2017 .

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.

A. Jimeno, T. Seiwert, A. Psyrri, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.

D. Shin, T. Seiwert, S. Best, 2023, The Laryngoscope.

A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover.

T. Seiwert, E. Cohen, D. Cupissol, 2013 .

A Randomized, Open-Label, Phase II Study of Afatinib Versus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

T. Seiwert, E. Cohen, D. Cupissol, 2012 .

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma

T. Seiwert, J. Adashek, Rodrigo de Castro Luna, 2023, npj Precision Oncology.

Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cisplatin therapy.

T. Seiwert, R. Mehra, J. Grilley-Olson, 2018 .

T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma.

T. Seiwert, Zhixiang Zuo, A. Husain, 2014 .